Adil Daud MD

Melanoma

UCSF

1825 4th StPCMBSan Francisco, CA 94143
Phone+1 415-353-9900

Dr. Daud is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Daud's full profile Already have an account?

Summary

Im a medical oncologist specializing in melanoma

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1997 - 2000
Indiana University School of MedicineResidency, Internal Medicine, 1994 - 1997
Government Medical College NagpurClass of 1985

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 2008 - 2028
FL State Medical License 2001 - 2010
NY State Medical License 1997 - 2003
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory EHR Suite, Epic Systems Corporation, 2013-2014, 2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012-2014, 2017
Super Doctor SuperDoctors.com

Clinical Trials

Trial of pIL-12 Electroporation Malignant Melanoma Start of enrollment: 2012 Feb 14
COMPLETED
PHASE2
A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma
COMPLETED
PHASE1, PHASE2

Publications & Presentations

PubMed

1 citations
The paradox of escalating immunotherapy for uveal melanoma liver metastases.
Paul Wong, Tommaso Pollini, Sophia Hernandez, Shao Tao, Guilin Qiao
HPB. 2026-09-01
A Technique for the Generation of Mucosal and Acral Melanoma Cell Lines.
Ishani Banik, Sugandha Basu, Meng Wang, Austin J Escobar, Veronica Steri
Pigment Cell & Melanoma Research. 2026-09-01
2 citations
Lipid Nanoparticle-Encapsulated mRNA-2752 Encoding Human OX40L, IL-23, and IL-36γ plus Durvalumab Induces an Immunostimulatory Effect within the Tumor Microenvironment...
Randy F Sweis, Georgina V Long, Adil Daud, Salomon M Stemmer, Antonio Jimeno
Clinical Cancer Research. 2026-08-14

Lectures

Epacadostat plus nivolumab for advanced melanoma: Updated phase 2 results of the ECHO-204 study.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Bay Area Doctors Warn Cancer Patients Can’t Afford Delays Under Trump’s DirectivesJanuary 29th, 2025
Sequencing Matters – Combination Dabrafenib/Trametinib Versus Nivolumab/Ipilimumab for Advanced BRAF-Mutant Melanoma: The DREAMseq TrialMarch 9th, 2023
$OncoSec Hosting an Investor and Analyst Day Webinar Showcasing Positive KEYNOTE-695 Data in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma$
OncoSec Hosting an Investor and Analyst Day Webinar Showcasing Positive KEYNOTE-695 Data in Anti-PD-1 Checkpoint Refractory Metastatic MelanomaNovember 5th, 2020